Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

376
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
376
CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

345
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
345
Drug Therapy01:28

Drug Therapy

140
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
140
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

306
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
306
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

543
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
543
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.0K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time to embrace the whole: considering the replacement of psilocybin with <i>Psilocybe</i> spp. in psychedelic research and therapy.

Natural product research·2026
Same author

Classic psychedelics and personality: An updated systematic review.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Early-life exposure to Cannabidiol: Safety assessment of a chronic exposure in Caenorhabditis elegans.

Toxicology and applied pharmacology·2026
Same author

Ayahuasca and Public Health III: Health Status of a Sample of Ayahuasca Ceremony Attenders in Portugal.

Journal of psychoactive drugs·2026
Same author

Effects of ayahuasca on neuropsychological performance and social cognition: A systematic review.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Cannabidiol reduces the latency for the behavioral effect of escitalopram in chronically stressed male mice: involvement of NAPE-PLD expressed in parvalbumin-positive interneurons and the prefrontal cortex.

Neuropharmacology·2026

Related Experiment Video

Updated: Nov 9, 2025

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

676

Psychedelic Medicines in Major Depression: Progress and Future Challenges.

Jose Carlos Bouso1, Genís Ona2, Rafael G Dos Santos2,3,4

  • 1ICEERS (International Center for Ethnobotanical Education, Research & Service), Barcelona, Spain. jcbouso@iceers.org.

Advances in Experimental Medicine and Biology
|April 9, 2021
PubMed
Summary

Research into psychedelic drugs like psilocybin is growing for treating mental health disorders. These substances show promise, particularly when used alongside psychotherapy, offering new therapeutic avenues.

Keywords:
AyahuascaDepressionHallucinogensMental healthPsilocybinPsychedelics

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.2K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

330

Related Experiment Videos

Last Updated: Nov 9, 2025

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

676
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.2K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

330

Area of Science:

  • Psychiatry and Pharmacology
  • Neuroscience

Background:

  • Increasing research into psychedelic drug therapeutics.
  • Need for innovative psychiatric treatments.
  • Focus on psilocybin and ayahuasca for mental disorders like depression.

Purpose of the Study:

  • Provide an introduction to psychedelic research, including history and terminology.
  • Analyze recent clinical trials of psychedelic drug administration.
  • Describe neurobiological mechanisms and therapeutic potential.

Main Methods:

  • Literature review of historical psychedelic research.
  • Detailed analysis of published clinical trials.
  • Examination of neurobiological mechanisms of psychedelic compounds.

Main Results:

  • Psychedelic drug research is expanding.
  • Clinical trials are assessing safety and efficacy for mental disorders.
  • Neurobiological mechanisms are being elucidated, suggesting adjuvant roles in psychotherapy.

Conclusions:

  • Psychedelic drugs show therapeutic potential, especially as adjuncts in psychotherapy.
  • The field faces future challenges in research and clinical application.
  • Continued investigation is crucial for understanding and utilizing these novel treatments.